Hormone Therapy and Castration Resistance of Prostate Cancer

Hormone Therapy and Castration Resistance of Prostate CancerAuthor(s): Yoichi Arai, Osamu Ogawa\nFormat: Hardback\nPublisher: Springer Verlag, Singapore, Singapore\nImprint: Springer Verlag, Singapore\nISBN-13: 9789811070129, 978-9811070129\nSynopsis\nThis comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androg.